A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab

References

• SunCCBodurkaDCWeaverCBRankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancerSupport Care Cancer200513421922715538640
   PubMed Web of Science ®Google Scholar
• Poli-BigelliSRodrigues-PereiraJCaridesADAddition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin AmericaCancer200397123090309812784346
   PubMed Web of Science ®Google Scholar
• NavariRMAaproMAntiemetic prophylaxis for chemotherapy-induced nausea and vomitingN Engl J Med2016374141356136727050207
   PubMed Web of Science ®Google Scholar
• HeskethPJChemotherapy-induced nausea and vomitingN Engl J Med2008358232482249418525044
   PubMed Web of Science ®Google Scholar
• HawkinsRGrunbergSChemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomesClin J Oncol Nurs2009131546419193549
   PubMed Web of Science ®Google Scholar
• ChungSKAhnMJYooJYImplementation of best practice for chemotherapy-induced nausea and vomiting in an acute care settingInt J Evid Based Healthc201191323821332661
   PubMedGoogle Scholar
• GrunbergSMDeusonRRMavrosPIncidence of chemotherapy-induced nausea and emesis after modern antiemeticsCancer2004100102261226815139073
   PubMed Web of Science ®Google Scholar
• BocciaRVChemotherapy-induced nausea and vomiting: identifying and addressing unmet needsJ Clin Outcomes Manag2013208377384
   Google Scholar
• GrallaRJOsobaDKrisMGRecommendations for the use of antiemetics: evidence-based, clinical practice guidelinesJ Clin Oncol19991792971299410561376
   PubMed Web of Science ®Google Scholar
• KrisMGHeskethPJHerrstedtJConsensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapySupport Care Cancer2005132859615565277
   PubMed Web of Science ®Google Scholar
• HerrstedtJRapoportBWarrDAcute emesis: moderately emetogenic chemotherapySupport Care Cancer201119Suppl 1S15S2320680356
   PubMed Web of Science ®Google Scholar
• WickhamRBest practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for useJ Support Oncol201082 Suppl 1101520629453
   PubMedGoogle Scholar
• LikunZXiangJYiBXinDTaoZLA systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adultsOncologist201116220721621282670
   PubMed Web of Science ®Google Scholar
• BotrelTEClarkOAClarkLPaladiniLFaleirosEPegorettiBEfficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysisSupport Care Cancer201119682383220495832
   PubMed Web of Science ®Google Scholar
• SchwartzbergLBarbourSYMorrowGRBallinariGThornMDCoxDPooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)Support Care Cancer201422246947724141698
   PubMed Web of Science ®Google Scholar
• KimJSKimJYLeeSJMulticenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancerAnn Surg Treat Res201487191325025021
   PubMed Web of Science ®Google Scholar
• NavariRMPalonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonistExpert Opin Drug Metab Toxicol20095121577158619929251
   PubMed Web of Science ®Google Scholar
• RojasCStathisMThomasAGPalonosetron exhibits unique molecular interactions with the 5-HT3 receptorAnesth Analg2008107246947818633025
   PubMed Web of Science ®Google Scholar
• RojasCLiYZhangJThe antiemetic 5-HT3 receptor antagonist palonosetron inhibits substance P-mediated responses in vitro and in vivoJ Pharmacol Exp Ther2010335236236820724484
   PubMed Web of Science ®Google Scholar
• RojasCThomasAGAltJPalonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor functionEur J Pharmacol20106262–319319919836386
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Antiemesis Version 1Fort Washington (PA)NCCN2015
   Google Scholar
• BaschEPrestrudAAHeskethPJKrisMGSomerfieldMRLymanGHAntiemetic use in oncology: updated guideline recommendations from ASCOAm Soc Clin Oncol Educ Book201253254024451791
   PubMedGoogle Scholar
• RozziANardoniCCoronaMPalonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II studySupport Care Cancer201119569770120467757
   PubMed Web of Science ®Google Scholar
• AffrontiMLBrickhouseAMarcelloJA phase II single arm trial of palonosetron (PALO) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in malignant glioma (MG) patients receiving irinotecan in combination with bevacizumabNeuro Oncol2009115656
   Web of Science ®Google Scholar
• FeinbergBGilmoreJHaislipSImpact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapySupport Care Cancer201220361562321761096
   PubMed Web of Science ®Google Scholar
• DeckerGMDeMeyerESKiskoDLMeasuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapyJ Support Oncol20064135415216444851
   PubMedGoogle Scholar
• O’BrienPCFlemingTRA multiple testing procedure for clinical trialsBiometrics1979353549556497341
   PubMed Web of Science ®Google Scholar
• Cancer Therapy Evaluation ProgramCommon Terminology Criteria for Adverse Events v3.0 (CTCAE)Bethesda (MD)CTEP2006
   Google Scholar
• BrearleySGClementsCVMolassiotisAA review of patient self-report tools for chemotherapy-induced nausea and vomitingSupport Care Cancer200816111213122918551323
   PubMed Web of Science ®Google Scholar
• MartinARPearsonJDCaiBElmerMHorganKLindleyCAssessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recallSupport Care Cancer200311852252712827483
   PubMed Web of Science ®Google Scholar
• MartinARCaridesADPearsonJDFunctional relevance of antiemetic control: experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitantEur J Cancer200339101395140112826042
   PubMed Web of Science ®Google Scholar
• CellaDEtonDTLaiJSPetermanAHMerkelDECombining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scalesJ Pain Symptom Manage200224654756112551804
   PubMed Web of Science ®Google Scholar
• MartinCGRubensteinEBEltingLSKimYJOsobaDMeasuring chemotherapy-induced nausea and emesisCancer200398364565512879484
   PubMed Web of Science ®Google Scholar
• BallatoriERoilaFImpact of nausea and vomiting on quality of life in cancer patients during chemotherapyHealth Qual Life Outcomes200314614521717
   PubMedGoogle Scholar
• AffrontiMLSchneiderSMHerndonJE2ndSchlundtSFriedmanHSAdherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practiceSupport Care Cancer20142271897190524570103
   PubMed Web of Science ®Google Scholar